
    
      Detailed histories of all participants were obtained, and systemic and rheumatologic
      examinations were performed. We excluded all participants who had a history of
      hyperlipidemia, liver, renal, hematological, familial thyroid, neoplastic, autoimmune
      infectious diseases and receiving anti-inflammatory drugs.

      We measured serum galectin-3 levels using a commercial chemiluminescent microparticle
      immunoassay. The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was used to
      assess disease activity in AS patients.
    
  